Memory Pharmaceuticals has announced a positive Phase II roof-of-concept trial of MEM 3454 in 80 patients with Alzheimer's disease over an eight week treatment period. The primary endpoint of the trial was the change from baseline in the Quality of Episodic Secondary Memory (QESM) factor score of the Cognitive Drug Research (CDR) battery. This is good news for Memory, which announced in mid-October that another drug, MEM 1003, failed a Phase IIa study.
"This data is consistent with our preclinical and Phase 1 results and reinforces our belief that MEM 3454 warrants continued development. We look forward to commencing our Phase IIa trial of MEM 3454 in cognitive impairment associated with schizophrenia in the near term."
- check out this press release for more